Marker Therapeutics (NASDAQ:MRKR – Get Free Report) and Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, risk, profitability, valuation, dividends and earnings. Volatility and Risk Marker Therapeutics has a beta […]
Jazz Pharmaceuticals (JAZZ) Overweight Rating Reaffirmed at Cantor Fitzgerald themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Cantor Fitzgerald reaffirmed their overweight rating on shares of Jazz Pharmaceuticals (NASDAQ:JAZZ – Free Report) in a research note issued to investors on Monday morning, PriceTargets.com reports. Cantor Fitzgerald also issued estimates for Jazz Pharmaceuticals’ FY2023 earnings at $14.27 EPS and FY2024 earnings at $15.79 EPS. Other analysts have also issued research reports about the […]
By Denny Jacob American depositary receipts of Avadel Pharmaceuticals tumbled 14% to $13.13 on Friday after a lawsuit was filed in the U.S. District Court for the District of Columbia alleging that the U.S. Food and Drug Administration unlawfully .
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) has filed suit against the FDA for approving Avadel Pharmaceuticals Plc's (NASDAQ: AVDL) Lumryz (sodium oxybate extended-release) for cataplexy or excessive day